Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/11/2025

Norursodeoxycholic Acid as a Therapeutic Agent

Introduction to NorUDCA

  • Norursodeoxycholic acid (norUDCA) is a structurally distinct side-chain-shortened derivative of UDCA, not a conjugated form of UDCA 1, 2

Pharmacological Properties

  • The resistance to conjugation gives norUDCA distinct therapeutic properties, including anti-cholestatic, anti-inflammatory, anti-fibrotic, and antiproliferative effects that differ from standard UDCA 3

Clinical Applications

  • NorUDCA is being investigated as a novel therapeutic agent for primary sclerosing cholangitis (PSC), with phase II trials showing dose-dependent reductions in alkaline phosphatase levels (up to -26% at 1,500mg/d) with an excellent safety profile 1, 2
  • The European Association for the Study of the Liver identifies norUDCA as a distinct "novel bile acid-based therapeutic option" separate from UDCA, alongside FXR agonists and other emerging therapies 1, 2

REFERENCES

3

Norursodeoxycholic Acid for Liver Fibrosis Treatment [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025